Hereditary disorders of collecting duct sodium and potassium transport

Molecular and Genetic Basis of Renal Disease

Volumn , Issue , 2008, Pages 251-268

  Ellison, David H ^a   Thomas, Christie P ^b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 57049181123     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-0252-9.50020-3     Document Type: Chapter

References (177)

1. Frindt G, Palmer LG Na channels in the rat connecting tubule. Am J Physiol Renal Physiol 2004, 286:F669-F674.
2. Rubera I, Loffing J, Palmer LG, et al. Collecting duct-specific gene inactivation of α-ENaC in the mouse kidney does not impair sodium and potassium balance. J Clin Invest 2003, 112:554-565.
3. Quinn SJ, Williams GH Regulation of aldosterone secretion. Annu Rev Physiol 1988, 50:409-426.
4. Spat A, Hunyady L Control of aldosterone secretion: A model for convergence in cellular signaling pathways. Physiol Rev 2004, 84:489-539.
5. Funder J, Pearce P, Smith R, Smith A Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583-585.
6. Quinkler M, Stewart PM Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003, 88:2384-2392.
7. de la Rosa DA, Canessa CM, Fyfe GK, Zhang P Structure and regulation of amiloride-sensitive sodium channels. Annu Rev Physiol 2000, 62:573-594.
8. Kellenberger S, Schild L Epithelial sodium channel/degenerin family of ion channels: A variety of functions for a shared structure. Physiol Rev 2002, 82:735-767.
9. + homeostasis and hypertension. Endocr Rev 2002, 23:258-275.
10. + channel regulation. Am J Physiol Renal Physiol 2001, 281:F469-F477.
11. Fotia AB, Dinudom A, Shearwin KE, et al. The role of individual Nedd4-2 (KIAA0439) WW domains in binding and regulating epithelial sodium channels. FASEB J 2003, 17:70-72.
12. Itani OA, Campbell JR, Herrero J, et al. Alternate promoters and variable splicing lead to hNedd4-2 isoforms with a C2 domain and varying number of WW domains. Am J Physiol Renal Physiol 2003, 285:F916-F929.
13. + channel trafficking. Endocrinology 2005, 146:5079-5085.
14. Loffing J, Flores SY, Staub O Sgk kinases and their role in epithelial transport. Annu Rev Physiol 2006, 68:16.11-16.30.
15. +channel. FASEB J 2001, 15:204-214.
16. Itani OA, Stokes JB, Thomas CP Nedd4-2 isoforms differentially associate with ENaC and regulate its activity. Am J Physiol Renal Physiol 2005, 289:F334-F446.
17. Garty H, Palmer LG Epithelial sodium channels: function, structure, and regulation. Physiol Rev 1997, 77:359-396.
18. Firsov D, Gautschi I, Merillat AM, et al. The heterotetrameric architecture of the epithelial sodium channel (ENaC). EMBO J 1998, 17:344-352.
19. Snyder PM, Cheng C, Prince LS, et al. Electrophysiological and biochemical evidence that DEG/ENaC cation channels are composed of nine subunits. J Biol Chem 1998, 273:681-684.
20. Kosari F, Sheng S, Li J, et al. Subunit stoichiometry of the epithelial sodium channel. J Biol Chem 1998, 273:13469-13474.
21. Loffing J, Pietri L, Aregger F, et al. Differential subcellular localization of ENaC subunits in mouse kidney in response to high- and low-Na diets. Am J Physiol Renal Physiol 2000, 279:F252-F258.
22. Loffing J, Zecevic M, Feraille E, et al. Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system: Possible role of SGK. Am J Physiol Renal Physiol 2001, 280:F675-F682.
23. Mick VE, Itani OA, Loftus RW, et al. The α-subunit of the epithelial sodium channel is an aldosterone-induced transcript in mammalian collecting ducts, and this transcriptional response is mediated via distinct cis-elements in the 5' flanking region of the gene. Mol Endocrinol 2001, 15:575-588.
24. Webster MK, Goya L, Ge Y, et al. Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. Mol Cell Biol 1993, 13:2031-2040.
25. Itani OA, Liu KZ, Cornish KL, et al. Glucocorticoids stimulate human SGK1 gene expression by activation of a hormone response element in its 5' flanking region. Am J Physiol Endocrinol Metab 2002, 283:E971-E979.
26. +channel cell surface expression. EMBO J 2001, 20:7052-7059.
27. Snyder PM, Olson DR, Thomas BC SGK modulates Nedd4-2-mediated inhibition of ENaC. J Biol Chem 2002, 277:5-8.
28. + channels by phosphorylation-dependent interaction with Nedd4-2 ubiquitin ligase. J Biol Chem 2005, 280:13187-13194.
29. Bhalla V, Daidie D, Li H, et al. SGK1 regulates ubiquitin ligase Nedd4-2 by inducing interaction with 14-3-3. Mol Endocrinol 2005, 19:3073-3084.
30. Diakov A, Korbmacher C A novel pathway of ENaC activation involves an SGK1 consensus motif in the C terminus of the channel's α-subunit. J Biol Chem 2004, 279:38134-38142.
31. Ring Am, Leng Q, Rinehart J, et al. An SGK1 site in WNK4 regulates Na+ channel and K+ channel activity and has implications for aldosterone signaling and K+ homeostasis. PNAS 2007, 104:4025-4029.
32. Xu BE, Stippec S, Chu PY, et al. WNK1 activates SGK1 to regulate the epithelial sodium channel. Proc Natl Acad Sci U S A 2005, 102:10315-10320.
33. Velazquez H, Bartiss A, Bernstein P, Ellison DH Adrenal steroids stimulate thiazide-sensitive NaCl transport by rat renal distal tubules. Am J Physiol 1996, 270:F211-F219.
34. Kim GH, Masilamani S, Turner R, et al. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci U S A 1998, 95:14552-14557.
35. Wang XY, Masilamani S, Nielsen J, et al. The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest 2001, 108:215-222.
36. Halperin ML, Kamel KS Dynamic interactions between integrative physiology and molecular medicine: The key to understand the mechanism of action of aldosterone in the kidney. Can J Physiol Pharmacol 2000, 78:587-594.
37. Wang W Renal potassium channels: Recent developments. Curr Opin Nephrol Hypertens 2004, 13:549-555.
38. + channel ROMK1. J Am Soc Nephrol 2002, 13:2823-2830.
39. Yoo D, Kim BY, Campo C, et al. Cell surface expression of the ROMK (Kir 1.1) channel is regulated by the aldosterone-induced kinase, SGK1, and protein kinase A. J Biol Chem 2003, 278:23066-23075.
40. O'Reilly M, Marshall E, Speirs HJL, Brown RW WNK1, a gene within a novel blood pressure control pathway, tissue-specifically generates radically different isoforms with and without a kinase domain. J Am Soc Nephrol 2003, 14:2447-2456.
41. Lazrak A, Liu Z, Huang C-L Antagonistic regulation of ROMK by long and kidney specific isoforms. Proc Natl Acad Sci U S A 2006, 103:1615-1620. Epub.
42. O'Reilly M, Marshall E, MacGillvray T, et al. Two WNKs on a changing diet. J Am Soc Nephrol 2006, 17:2402-2413.
43. Wang W Regulation of renal K transport by dietary K intake. Annu Rev Physiol 2004, 66:547-569.
44. + secretion. Nat Genet 2003, 35:372-376.
45. + secretion in the cortical collecting duct is mediated by a maxi-K channel. Am J Physiol Renal Physiol 2001, 280:F786-F793.
46. i response of principal and intercalated cells in cortical collecting duct. Am J Physiol Renal Physiol 2003, 285:F998-F1012.
47. Wingo CS, Smolka AJ Function and structure of H-K-ATPase in the kidney. Am J Physiol Renal Physiol 1995, 269:F1-F16.
48. +-ATPases: Regulation and role in pathophysiological states. Am J Physiol Renal Physiol 1999, 276:F799-F811.
49. Petrovic S, Spicer Z, Greeley T, et al. Novel Schering and ouabain-insensitive potassium-dependent proton secretion in the mouse cortical collecting duct. Am J Physiol Renal Physiol 2002, 282:F133-F143.
50. DuBose TD, Seldin DW, Kokko JP Segmental chloride reabsorption in the rat nephron as a function of load. Am J Physiol 1978, 234:F97-F105.
51. Rector FC, Clapp JR Evidence for active chloride reabsorption in the distal renal tubule of the rat. J Clin Invest 1962, 41:101-107.
52. Uchida S, Sasaki S Function of chloride channels in the kidney. Annu Rev Physiol 2005, 67:759-778.
53. Velazquez H, Silva T, Andujar E, et al. The distal convoluted tubule of rabbit kidney does not express a functional sodium channel. Am J Physiol Renal Physiol 2001, 280:F530-F539.
54. Hayama A, Rai T, Sasaki S, Uchida S Molecular mechanisms of Bartter syndrome caused by mutations in the BSND gene. Histochem Cell Biol 2003, 119:485-493.
55. Weinstein AM A mathematical model of rat distal convoluted tubule (I): Cotransporter function in early DCT. Am J Physiol Renal Physiol 2005, 289:F699-F720.
56. Weinstein AM A mathematical model of rat distal convoluted tubule (II): Potassium secretion along the connecting segment. Am J Physiol Renal Physiol 2005, 289:F721-F741.
57. Kobayashi K, Uchida S, Mizutani S, et al. Intrarenal and cellular localization of CLC-K2 protein in the mouse kidney. J Am Soc Nephrol 2001, 12:1327-1334.
58. Kobayashi K, Uchida S, Okamura HO, et al. Human CLC-KB gene promoter drives the EGFP expression in the specific distal nephron segments and inner ear. J Am Soc Nephrol 2002, 13:1992-1998.
59. - exchanger associated with inherited distal renal tubular acidosis. Clin Exp Nephrol 2004, 8:1-11.
60. Liddle GW, Bledsoe T, Coppage WS A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Transactions Assoc Am Physicians 1963, 76:199-213.
61. Botero-Velez M, Curtis JJ, Warnock DG Liddle's syndrome revisited-A disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994, 330:178-181.
62. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: Heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994, 79:407-414.
63. Hansson JH, Nelson-Williams C, Suzuki H, et al. Human hypertension caused by mutation in the gamma subunit of the epithelial sodium channel: Genetic heterogeneity of Liddle's syndrome. Nat Genet (Lond) 1995, 11:76-82.
64. Hansson JH, Schild L, Lu Y, et al. A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci U S A 1995, 92:11495-11499.
65. Tamura H, Schild L, Enomoto N, et al. Liddle disease caused by a missense mutation of beta subunit of the epithelial sodium channel gene. J Clin Invest 1996, 97:1780-1784.
66. Inoue J, Iwaoka T, Tokunaga H, et al. A family with Liddle's syndrome caused by a new missense mutation in the beta subunit of the epithelial sodium channel. J Clin Endocrinol Metab 1998, 83:2210-2213.
67. Hiltunen TP, Hannila-Handelberg T, Petajaniemi N, et al. Liddle's syndrome associated with a point mutation in the extracellular domain of the epithelial sodium channel gamma subunit. J Hypertens 2002, 20:2383-2390.
68. Warnock DG Liddle syndrome: An autosomal dominant form of human hypertension. Kidney Int 1998, 53:18-24.
69. Assadi F, Kimura R, Subramanian U, Patel S Liddle syndrome in a newborn infant. Pediatr Nephrol 2002, 17:609.
70. + channel. Cell 1995, 83:969-978.
71. Schild L, Lu Y, Gautschi I, et al. Identification of a PY motif in the epithelial Na channel subunits as a target sequence for mutations causing channel activation found in Liddle syndrome. EMBO J 1996, 15:2381-2387.
72. Firsov D, Schild L, Gautschi I, et al. Cell surface expression of the epithelial Na channel and a mutant causing Liddle syndrome: A quantitative approach. Proc Natl Acad Sci U S A 1996, 93:15370-15375.
73. Kyuma M, Ura N, Torii T, et al. A family with Liddle's syndrome caused by a mutation in the beta subunit of the epithelial sodium channel. Clin Exp Hypertens 2001, 23:471-478.
74. Jeunemaitre X, Bassilana F, Persu A, et al. Genotype-phenotype analysis of a newly discovered family with Liddle's syndrome. J Hypertens 1997, 15:1091-1100.
75. Nakano Y, Ishida T, Ozono R, et al. A frameshift mutation of beta subunit of epithelial sodium channel in a case of isolated Liddle syndrome. J Hypertens 2002, 20:2379-2382.
76. Gao PJ, Zhang KX, Zhu DL, et al. Diagnosis of Liddle syndrome by genetic analysis of beta and gamma subunits of epithelial sodium channel-A report of five affected family members. J Hypertens 2001, 19:885-889.
77. Yamashita Y, Koga M, Takeda Y, et al. Two sporadic cases of Liddle's syndrome caused by de novo ENaC mutations. Am J Kidney Dis 2001, 37:499-504.
78. Ciechanowicz A, Dolezel Z, Placha G, et al. Liddle syndrome caused by P616R mutation of the epithelial sodium channel beta subunit. Pediatr Nephrol 2005, 20:837-838.
79. Furuhashi M, Kitamura K, Adachi M, et al. Liddle's syndrome caused by a novel mutation in the proline-rich PY motif of the epithelial sodium channel β-subunit. J Clin Endocrinol Metab 2005, 90:340-344.
80. Freundlich M, Ludwig M A novel epithelial sodium channel beta-subunit mutation associated with hypertensive Liddle syndrome. Pediatr Nephrol 2005, 20:512-515.
81. Uehara Y, Sasaguri M, Kinoshita A, et al. Genetic analysis of the epithelial sodium channel in Liddle's syndrome. J Hypertens 1998, 16:1131-1135.
82. Pradervand S, Wang Q, Burnier M, et al. A mouse model for Liddle's syndrome. J Am Soc Nephrol 1999, 10:2527-2533.
83. Pradervand S, Vandewalle A, Bens M, et al. Dysfunction of the epithelial sodium channel expressed in the kidney of a mouse model for Liddle's syndrome. J Am Soc Nephrol 2003, 14:2219-2228.
84. Baker E, Jeunemaitre X, James Portal A, et al. Abnormalities of nasal potential difference measurement in Liddle's syndrome. J Clin Invest 1998, 102:10-14.
85. + channels by beta-subunit mutation. Am J Physiol 1996, 270:C208-C213.
86. Cheek DB, Perry JW A salt wasting syndrome in infancy. Arch Dis Child 1958, 33:252-256.
87. Chang SS, Grunder S, Hanukoglu A, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996, 12:248-253.
88. Strautnieks SS, Thompson RJ, Gardiner RM, Chung E A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Nat Genet (Lond) 1996, 13:248-250.
89. Kerem E, Bistritzer T, Hanukoglu A, et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999, 341:156-162.
90. Edelheit O, Hanukoglu I, Gizewska M, et al. Novel mutations in epithelial sodium channel (ENaC) subunit genes and phenotypic expression of multisystem pseudohypoaldosteronism. Clin Endocrinol (Oxf) 2005, 62:547-553.
91. Thomas CP, Zhou J, Liu KZ, et al. Systemic pseudohypoaldosteronism from deletion of the promoter region of the human bENaC subunit. Am J Respir Cell Mol Bio 2002, 27:314-319.
92. Schaedel C, Marthinsen L, Kristoffersson AC, et al. Lung symptoms in pseudohypoaldosteronism type 1 are associated with deficiency of the a-subunit of the epithelial sodium channel. J Pediatr 1999, 135:739-745.
93. Greenberg D, Abramson O, Phillip M Fetal pseudohypoaldosteronism: Another cause of hydramnios. Acta Paediatr, Int J Paediatr 1995, 84:582.
94. Narchi H, Santos M, Kulaylat N Polyhydramnios as a sign of fetal pseudohypoaldosteronism. Int J Gynecol Obstet 2000, 69:53.
95. Oberfield SE, Levine LS, Carey RM, et al. Pseudohypoaldosteronism: Multiple target organ unresponsiveness to mineralocorticoid hormones. J Clin Endocrinol Metab 1979, 48:228-234.
96. Hanukoglu A Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities with either renal or multiple target organ defects. J Clin Endocrinol Metab 1991, 73:936-944.
97. Urbatsch A, Paller AS Pustular miliaria rubra: A specific cutaneous finding of type I pseudohypoaldosteronism. Pediatr Dermatol 2002, 19:317-319.
98. Martin JM, Calduch L, Monteagudo C, et al. Clinico-pathological analysis of the cutaneous lesions of a patient with type I pseudohypoaldosteronism. J Eur Acad Dermatol Venereol 2005, 19:377-379.
99. Malagon-Rogers M A patient with pseudohypoaldosteronism type 1 and respiratory distress syndrome. Pediatr Nephrol 1999, 13:484-486.
100. Akcay A, Yavuz T, Semiz S, et al. Pseudohypoaldosteronism type 1 and respiratory distress syndrome. J Pediatr Endocrinol Metab 2002, 15:1557-1561.
101. Bonny O, Knoers N, Monnens L, Rossier BC A novel mutation of the epithelial Na+ channel causes type 1 pseudohypoaldosteronism. Pediatr Nephrol 2002, 17:804-808.
102. Hummler E, Barker P, Gatzy J, et al. Early death due to defective neonatal lung liquid clearance in aENaC-deficient mice. Nat Genet 1996, 12:325-328.
103. Hummler E, Barker P, Talbot C, et al. A mouse model for the renal salt-wasting syndrome pseudohypoaldosteronism. Proc Nat Acad Sci USA 1997, 94:11710-11715.
104. + channel in mice: Hyperkalemia and neonatal death associated with pseudohypoaldosteronism phenotype. Proc Natl Acad Sci U S A 1999, 96:1727-1731.
105. Barker PM, Nguyen MS, Gatzy JT, et al. Role of gENaC subunit in lung liquid clearance and electrolyte balance in newborn mice. Insights into perinatal adaptation and pseudohypoaldosteronism. J Clin Invest 1998, 102:1634-1640.
106. Prince LS, Launspach JL, Geller DS, et al. Absence of amiloride-sensitive sodium absorption in the airway of an infant with pseudohypoaldosteronism. J Pediatr 1999, 135:786-789.
107. Zennaro MC, Lombes M Mineralocorticoid resistance. Trends Endocrinol Metab 2004, 15:264.
108. Rosler A The natural history of salt-wasting disorders of adrenal and renal origin. J Clin Endocrinol Metab 1984, 59:689-700.
109. Viemann M, Peter M, Lopez-Siguero JP, et al. Evidence for genetic heterogeneity of pseudohypoaldosteronism type 1: Identification of a novel mutation in the human mineralocorticoid receptor in one sporadic case and no mutations in two autosomal dominant kindreds. J Clin Endocrinol Metab 2001, 86:2056-2059.
110. Tajima T, Kitagawa H, Yokoya S, et al. A novel missense mutation of mineralocorticoid receptor gene in one Japanese family with a renal form of pseudohypoaldosteronism type 1. J Clin Endocrinol Metab 2000, 85:4690-4694.
111. Sartorato P, Lapeyraque AL, Armanini D, et al. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab 2003, 88:2508-2517.
112. Sartorato P, Cluzeaud F, Fagart J, et al. New naturally occurring missense mutations of the human mineralocorticoid receptor disclose important residues involved in dynamic interactions with deoxyribonucleic acid, intracellular trafficking, ligand binding. Mol Endocrinol 2004, 18:2151-2165.
113. + metabolism. Proc Natl Acad Sci U S A 1998, 95:9424-9429.
114. Bleich M, Warth R, Schmidt-Hieber M, et al. Rescue of the mineralocorticoid receptor knock-out mouse. Pflugers Arch-Eur J Physiol 1999, 438:245-254.
115. + channel via glucocorticoids in mineralocorticoid receptor knockout mice. Pfluegers Arch-Eur J Physiol 2001, 443:297-305.
116. New MI, Levine LS, Biglieri EG, et al. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 1977, 44:924-933.
117. Cooper M, Stewart P The syndrome of apparent mineralocorticoid excess. QJM 1998, 91:453-455.
118. Wilson RC, Nimkarn S, New MI Apparent mineralocorticoid excess. Trends Endocrinol Metabol 2001, 12:104-111.
119. White PC, Mune T, Rogerson FM, et al. Molecular analysis of 11[beta]-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Steroids 1997, 62:83-88.
120. Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1998, 83:2244-2254.
121. Stewart PM, Krozowski ZS, Gupta A, et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996, 347:88-91.
122. Kotelevtsev Y, Brown RW, Fleming S, et al. Hypertension in mice lacking 11ß-hydroxysteroid dehydrogenase type 2. J Clin Invest 1999, 103:683-689.
123. Monder C, Shackleton CH, Bradlow HL, et al. The syndrome of apparent mineralocorticoid excess: Its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab 1986, 63:550-557.
124. Shackleton CH, Rodriguez J, Arteaga E, et al. Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: Corticosteroid metabolite profiles of four patients and their families. Clin Endocrinol (Oxf) 1985, 22:701-712.
125. Palermo M, Delitala G, Mantero F, et al. Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): Diagnostic value of urinary free cortisol and cortisone. J Endocrinol Invest 2001, 24:17-23.
126. Mantero F, Palermo M, Petrelli MD, et al. Apparent mineralocorticoid excess: Type I and type II. Steroids 1996, 61:193-196.
127. Geller DS, Farhi A, Pinkerton N, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000, 289:119-123.
128. Paver WK, Pauline GJ Hypertension and hyperpotassemia without renal disease in a young male. Med J Aust 1964, 2:305-306.
129. Gordon RD, Geddes RA, Pawsey CG, O'Halloran MW Hypertension and severe hyperkalaemia associated with suppression of renin and aldosterone and completely reversed by dietary sodium restriction. Australas Ann Med 1970, 19:287-294.
130. Spitzer A, Edelmann C Short stature, hyperkalemia and acidosis: A defect in renal transport of potassium. Kidney Int 1973, 3:251-257.
131. Weinstein SF, Allan DME, Mendoza SA Hyperkalemia, acidosis, and short stature associated with a defect in renal potassium excretion. J Pediatr 1974, 85:355-358.
132. Lee MR, Ball SG, Thomas TH, Morgan DB Hypertension and hyperkalaemia responding to bendrofluazide. Q J Med 1979, 48:245-258.
133. Grekin RJ, Nicholls MG, Padfield PL Disorders of chloriuretic hormone secretion. Lancet 1979, 1:1116-1118.
134. Iitaka K, Watanabe N, Asakura A, et al. Familial hyperkalemia, metabolic acidosis and short stature with normal renin and aldosterone levels. Int J Ped Neph 1980, 28:782A.
135. Schambelan M, Sebastian A, Rector FC Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): Role of increased renal chloride reabsorption. Kidney Int 1981, 19:716-727.
136. Disse-Nicodeme S, Achard JM, Desitter I, et al. A new locus on chromosome 12p13.3 for pseudohypoaldosteronism type II, an autosomal dominant form of hypertension. Am J Hum Genet 2000, 67:302-310.
137. Disse-Nicodeme S, Achard JM, Potier J, et al. Familial hyperkalemic hypertension (Gordon syndrome): Evidence for phenotypic variability in a study of 7 families. Adv Nephrol Necker Hosp 2001, 31:55-68.
138. Wilson FH, Disse-Nicodeme S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science 2001, 293:1107-1112.
139. Achard JM, Disse-Nicodeme S, Fiquet-Kempf B, Jeunemaitre X Phenotypic and genetic heterogeneity of familial hyperkalaemic hypertension (Gordon syndrome). Clin Exp Pharmacol Physiol 2001, 28:1048-1052.
140. Achard JM, Warnock DG, Disse-Nicodeme S, et al. Familial hyperkalemic hypertension: Phenotypic analysis in a large family with the WNK1 deletion mutation. Am J Med 2003, 114:495-498.
141. Farfel Z, Iaina A, Rosenthal T, et al. Familial hyperpotassemia and hypertension accompanied by normal plasma aldosterone levels: Possible hereditary cell membrane defect. Arch Intern Med 1978, 138:1828-1832.
142. Mansfield TA, Simon DB, Farfel Z, et al. Multilocus linkage of familial hyperkalaemia and hypertension, pseudohypoaldosteronism type II, to chromosomes 1q31-42 and 17p11-q21. Nat Genet 1997, 16:202-205.
143. Simon DB, Farfel Z, Ellison D, et al. Examination of the thiazide-sensitive Na-Cl cotransporter as a candidate gene in Gordon's syndrome. JASN 1995, 6:632.
144. Disse-Nicodeme S, Desitter I, Fiquet-Kempf B, et al. Genetic heterogeneity of familial hyperkalaemic hypertension. J Hypertens 2001, 19:1957-1964.
145. Xu B, English JM, Wilsbacher JL, et al. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J Biol Chem 2000, 275:16795-16801.
146. Xu BE, Min X, Stippec S, et al. Regulation of WNK1 by an autoinhibitory domain and autophosphorylation. J Biol Chem 2002, 277:48456-48462.
147. Moriguchi T, Urushiyama S, Hisamoto N, et al. WNK1 regulates phosphorylation of cation-chloride-coupled cotransporters via the STE20-related kinases, SPAK and OSR1. J Biol Chem 2005, 280:42685-42693.
148. Wang Z, Yang CL, Ellison DH Comparison of WNK4 and WNK1 kinase and inhibiting activities. Biochem Biophys Res Commun 2004, 317:939-944.
149. Lee BH, Min X, Heise CJ, et al. WNK1 phosphorylates synaptotagmin 2 and modulates its membrane binding. Mol Cell 2004, 15:741-751.
150. Lenertz LY, Lee BH, Min X, et al. Properties of WNK1 and implications for other family members. J Biol Chem 2005, 280:26653-26658.
151. Mayan H, Vered I, Mouallem M, et al. Pseudohypoaldosteronism type II: Marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab 2002, 87:3248-3254.
152. Gordon RD Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension 1986, 8:93-102.
153. Mayan H, Munter G, Shaharabany M, et al. Hypercalciuria in familial hyperkalemia and hypertension accompanies hyperkalemia and precedes hypertension: Description of a large family with the Q565E WNK4 mutation. J Clin Endocrinol Metab 2004, 89:4025-4030.
154. Gordon RD, Klemm SA, Tunny TJ, Stowasser M Gordon's syndrome: A sodium-volume dependent form of hypertension with a genetic basis. Hypertension: Pathophysiology, Diagnosis, and Management 1995, 211-2123. Raven Press, New York. J.H. Laragh, B.M. Brenner (Eds.).
155. Sanjad SA, Mansour FM, Hernandez RH, Hill LL Severe hypertension, hyperkalemia, and renal tubular acidosis responding to dietary sodium restriction. Pediatrics 1982, 69:317-324.
156. Wayne VS, Stockigt JR, Jennings GL Treatment of mineralocorticoid-resistant renal hyperkalemia with hypertension (type II pseudohypoaldosteronism). Aust NZ J Med 1986, 16:221-223.
157. Rodriguez-Soriano J, Vallo A, Dominguez MJ 'Chloride-shunt' syndrome: An overlooked cause of renal hypercalciuria. Pediatr Nephrol 1989, 3:113-121.
158. Gereda JE, Bonilla-Felix M, Kalil B, Dewitt SJ Neonatal presentation of Gordon syndrome. J Pediatr 1996, 129:615-617.
159. Tokunaga Y, Yoshida I, Endo F, Kato H The effect of furosemide on a patient with hyperkalaemic hypertension and short stature. Eur J Pediatr 1995, 154:870.
160. Licht JH, Amundson D, Hsueh WA, Lombardo JV Familiar hyperkalemic acidosis. Q J Med 1985, 54:161-176.
161. Ellison DH Salt-wasting disorders. Acid-Base and Electrolyte Disorders 2002, 311-333. Saunders, Philadelphia. T. DuBose, L.L. Hamm (Eds.).
162. Yang CL, Angell J, Mitchell R, Ellison DH WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 2003, 111:1039-1045.
163. --transporting epithelia. Proc Natl Acad Sci U S A 2003, 100:663-668.
164. Wilson FH, Kahle KT, Sabath E, et al. Molecular pathogenesis of inherited hypertension with hyperkalemia: The Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A 2003, 100:680-684.
165. Yang CL, Zhu X, Wang Z, et al. Mechanisms of WNK1 and WNK4 interaction in the regulation of thiazide-sensitive NaCl cotransport. J Clin Invest 2005, 115:1379-1387.
166. Yamauchi K, Rai T, Kobayashi K, et al. Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. Proc Natl Acad Sci U S A 2004, 101:4690-4694.
167. -permeability is regulated by WNK4 kinase: Insight into normal physiology and hypertension. Proc Natl Acad Sci U S A 2004, 101:14877-14882.
168. Delaloy C, Lu J, Houot AM, et al. Multiple promoters in the WNK1 gene: One controls expression of a kidney-specific kinase-defective isoform. Mol Cell Biol 2003, 23:9208-9221.
169. Subramanya AR, Yang CL, Zhu X, Ellison DH Dominant-negative regulation of WNK1 by its kidney-specific kinase-defective isoform. Am J Physiol Renal Physiol 2005, 290:F617-F618.
170. +transport. Proc Natl Acad Sci U S A 2004, 101:17434-17439.
171. Stone RC, Vale P, Rosa FC Effect of hydrochlorothiazide in pseudohypoaldosteronism with hypercalciuria and severe hyperkalemia. Pediatr Nephrol 1996, 10:501-503.
172. Lalioti MD, Kahle KT, Toka HR, et al. Mutant WNK4 in mouse reveals mechanisms of pseudohypoaldosteronism type II. Nat Genet 2006, 38:1124-1132.
173. Yang S-S, Morimoto T, Rai T, et al. Molecular pathogenesis of pseudohypoaldosteronism type II: Generation and analysis of a Wnk4D561A/+ knockin mouse model. Cell Metabol 2007, 5:331-344.
174. Zambrowicz BP, Abuin A, Ramirez-Solis R, et al. Wnk1 kinase deficiency lowers blood pressure in mice: A gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci U S A 2003, 100:14109-14114.
175. Olyaei AJ, de Mattos AM, Bennett WM Immunosuppressant-induced nephropathy: Pathophysiology, incidence and management. Drug Saf 1999, 21:471-488.
176. Klemm SA, Gordon RD, Tunny TJ, Finn WL Biochemical correction in the syndrome of hypertension and hyperkalaemia by severe dietary salt restriction suggests renin-aldosterone suppression critical in pathophysiology. Clin Exp Pharmacol Physiol 1990, 17:191-195.
177. Brautbar N, Levi J, Rosler A, et al. Familial hyperkalemia, hypertension, hyporeninemia with normal aldosterone levels. A tubular defect in potassium handling. Arch Intern Med 1978, 138:607-610.